Cellectis board approves transformation to in vivo gene editing company
Cellectis said its board approved a strategic transformation to an in vivo gene editing company, with development focused on unspecified areas.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.